Menorrhagia is menstruation at a regular cyclical interval with excessive flow and duration; clinically, blood loss is in excess of 80 ml per cycle; or menses lasts longer than 7 days. The bleeding starts on schedule, but it is heavier than usual and may last longer than usual. It is one of the most common complaints in contemporary gynecology.
Each year a sum of around £7 million is spent on prescriptions in primary care to treat menorrhagia. It is the second most common gynaecological condition to be referred to hospital, accounting for around 12% of all gynaecological referrals.The term 'incidence' of Menorrhagia refers to the annual diagnosis rate, or the number of new cases of Menorrhagia diagnosed each year.
Menorrhagia can result in severe anemia. Of 115 women with physician-diagnosed menorrhagia, 58 percent reported a history of anemia, for which 89 percent received treatment.Additionally, 4 percent had received transfusion. Treatment of menorrhagia results in substantial improvement in quality of life.
Major research on disease:
Endometrial Ablation for Aplastic Anemia-Associated Menorrhagia.Treatment options will depend on the cause of menorrhagia, the severity of menorrhagia and the overall health of the patient. Some common treatments include iron supplements, oral contraceptives, ibuprofen, and progesterone.